Buyout rumors again from Proactive Investors.
In the market, vague and unconfirmed rumours were doing the rounds that drug group GlaxoSmithKline PLC (LON:GSK) could be among potential bidders for US rival Pacific Biosciences of California (NASDAQ: PACB).
Pacific’s shares have risen about 13% in the last month and were up 2.26% to US$9.95 in early Wall Street trading on Thursday.
Gossips reckoned Swiss group Roche had taken on advisers Greenhill to assess a possible approach, while Pacific was rumoured to have appointed Goldman Sachs to advise on any interest.
PACB partners with IMEC(Belgium) to develop their prototype ZMW, IMEC partners with MOSIS (Los Angeles) for prototype production. MOSIS partners with TSMC and Globalfoundries for large scale production.
Base calling has been a quagmire according to the cto in yesterday's presentation. They made some progress recently by changing the type of pore and base calling software. 1D sequencing has an accuracy of approximately 85%, 2D is approximately 95%. But 2D is technically unachievable in mass sequencing because of enormous computing requirement. So their product will be mostly using 1D sequencing in the future. To reduce systematic errors, they have to consider mixing different pores on the same chip, that will be technically very challenging. Systematic error alone will make their product useless in the diagnostic field. Again, these are their own words and we have yet to see actual data published by scientists who use their product. They do have a history of over promising in the past.
Don't worry about Nanopore yet. Their error rate, particularly their systematic error is currently an insurmountable obstacle for them, making them no match for pacbio in the near future.
The prototype product of minion from oxford nanopore appeared in early 2012. The error rate from nanopore is higher than SMRT, some of them seems to be systemic, which can not be corrected by repeated sequencing. There are minimal number of publications associated with the use of minion so far. They also seem to have difficulty in fabricating the minion product with consistent quality. I don't think nanopore could become a serious competitor against pacb in the near future.
According to the latest sc-13g filling.
Mitchell J. Blutt is an American physician-businessman, and he is one of the first physicians to play a prominent role on Wall Street by drawing on his medical training to identify investment potential in healthcare companies. He is the founder and CEO of the New York-based healthcare investment firm Consonance Capital and the former Executive Partner of J.P. Morgan Partners. He is also a Clinical Assistant Professor of Medicine in the Department of Medicine at Weill Cornell Medical College and the Graduate School of Medical Sciences of Cornell University.
Something interesting is going on?
ok, might not be new to you, first time I heard these:
we have seen greatly increased interest from companies in commercializing the product in markets outside the United States for its current indication and follow-on indications. Several of these companies are also interested in evaluating Disorazol Z. While much work remains to be done, we are hopeful that we can bring one or more transactions to conclusion.”
Mr. David A. Dodd, Chairman, President and CEO of the Company commented on the Company’s business development efforts, saying “With the recent DSMB recommendation that we complete our ZoptEC Phase 3 study of Zoptrex™, we have seen greatly increased interest from companies in commercializing the product in markets outside the United States for its current indication and follow-on indications. Several of these companies are also interested in evaluating Disorazol Z. While much work remains to be done, we are hopeful that we can bring one or more transactions to conclusion.”
surprised to see the minimal reaction to Dodd's comments, maybe that's just because of the market meltdown. We will see tomorrow